Actively Recruiting
Defibrotide for the Treatment of Severe COVID-19
Led by Brigham and Women's Hospital · Updated on 2024-05-10
42
Participants Needed
1
Research Sites
217 weeks
Total Duration
On this page
Sponsors
B
Brigham and Women's Hospital
Lead Sponsor
J
Jazz Pharmaceuticals
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this study is to evaluate the safety and feasibility of defibrotide in COVID-19 pneumonia.
CONDITIONS
Official Title
Defibrotide for the Treatment of Severe COVID-19
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Active COVID-19 infection confirmed by positive SARS-CoV-2 PCR
- Radiographic evidence of bilateral pulmonary infiltrates
- Life expectancy of at least 24 hours
- Score of 4 to 7 on the WHO ordinal scale
- Prophylactic anticoagulation allowed for cohort 1
- Therapeutic anticoagulation for active thrombosis, ECMO, or CRRT allowed for cohort 2 if no bleeding after 24 hours
- Patient or surrogate able to provide informed consent
You will not qualify if you...
- Clinically significant acute bleeding
- Use of thrombolytic therapy (e.g., t-PA)
- Hemodynamic instability requiring more than 1 vasopressor agent for cohort 1
- Hemodynamic instability requiring more than 2 vasopressor agents for cohort 2
- Known allergy or hypersensitivity to defibrotide
- Pregnant or lactating
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02214
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here